{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwIrN2pwKDA","founded_year":1950,"lastupdate":"2022-11-04T00:00:00.000Z","update_date":"2022-11-04T00:00:00.000Z","lastModified":"Feb 17, 2021","confidence_score":62,"active":1,"confidence_score_reason":"funding stage, product stage, sector, business model, video or image, funding rounds, markets, not claimed","urlname":"ferring-pharmaceuticals","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"description_edited":1,"tag_line_edited":1,"phone":"+97246309500 Ferring; +97288612009 BTG","registrar":"","biverification":"Yanina Wainscheinker","recentupdates":[{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-05 15:10:05.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2022-11-04 14:17:55.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2022-11-04 14:27:14.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-22 06:24:58.000000","last_name":"Levin","first_name":"Eran"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-08-07 05:07:36.000000","last_name":"Levin","first_name":"Eran"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-01-25 07:23:34.000000","last_name":"Levin","first_name":"Eran"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-01-25 16:24:24.000000","last_name":"Levin","first_name":"Eran"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2025-02-06 12:29:07.000000","last_name":"Levin","first_name":"Eran"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-01-25 07:23:34.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2022-11-04 14:27:02.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2022-11-04 13:15:17.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2022-11-04 14:20:18.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-05 14:41:59.000000","last_name":"Levin","first_name":"Eran"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2019-02-11 07:20:15.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"rom.lotan@gmail.com","source":"Manual","datetime":"2018-12-30 21:59:21.000000","last_name":"Lotan","first_name":"Rom"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2019-02-11 07:21:44.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2019-02-11 07:20:33.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-05-24 11:36:21.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-01-18 14:58:43.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-01-18 14:58:43.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-01-18 14:58:43.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-01-18 14:58:43.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-01-18 14:58:43.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-01-18 14:58:43.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-01-18 14:58:43.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-01-18 14:58:43.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-01-18 14:58:43.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-01-18 14:59:55.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2017-01-20 13:13:13.000000","last_name":"McCandless","first_name":"Katie"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2017-01-20 13:13:13.000000","last_name":"McCandless","first_name":"Katie"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2017-01-20 13:13:13.000000","last_name":"McCandless","first_name":"Katie"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-02 08:15:54.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-02 08:15:54.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-02 08:15:54.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-02 08:15:54.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-02 08:15:54.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-02 08:15:54.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-02 08:15:54.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-02 08:33:54.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-02 08:19:07.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-02 08:42:47.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-02 08:38:19.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-02 08:44:02.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-02 08:36:55.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-02 08:34:12.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-23 09:46:13.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-23 09:46:13.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-24 10:56:15.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-24 11:03:38.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-24 11:03:38.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-24 09:26:10.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-24 10:56:16.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-24 09:26:10.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-24 09:26:10.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-24 09:26:10.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-24 09:26:10.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-24 10:59:44.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-03 05:55:36.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-02 08:16:55.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-11-02 08:35:22.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-24 10:56:16.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-25 08:53:03.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-25 08:50:32.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-25 09:09:14.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-25 09:21:46.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-25 09:23:06.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-23 09:39:05.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-23 09:39:05.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-23 09:39:05.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-23 09:39:05.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-23 09:39:05.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-23 09:39:05.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-23 09:39:05.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-23 09:39:05.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-23 09:39:05.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-23 09:39:05.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-23 09:39:05.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-23 09:39:05.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-23 09:39:05.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-23 09:39:05.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-23 09:39:05.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-23 09:39:05.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-23 09:39:05.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2016-08-24 11:10:32.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-12-16 21:38:34.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-12-16 21:39:29.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-12-16 21:39:31.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-12-16 21:39:31.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-12-16 21:39:31.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-12-16 21:46:05.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-12-16 21:46:05.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-12-16 21:39:29.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yotamm1988@gmail.com","source":"Manual","datetime":"2021-02-17 14:36:18.000000","last_name":"Maman","first_name":"Yotam"},{"email":"lena.rogovina@gmail.com","source":"Manual","datetime":"2019-03-24 10:47:42.000000","last_name":"Rogovina","first_name":"Lena"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2019-03-25 12:41:16.000000","last_name":"McCandless","first_name":"Katie"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2019-03-25 12:41:16.000000","last_name":"McCandless","first_name":"Katie"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-12-16 21:39:28.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-12-16 21:39:34.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-12-16 21:46:10.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2022-11-04 14:27:14.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2022-11-04 13:15:17.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2022-11-04 13:15:17.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-03-20 06:24:48.000000","last_name":"Levin","first_name":"Eran"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-08-07 05:46:20.000000","last_name":"Levin","first_name":"Eran"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-05 14:22:58.000000","last_name":"Levin","first_name":"Eran"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-02-13 06:49:14.000000","last_name":"Levin","first_name":"Eran"}],"sectorverify":null,"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMGgoMMJDA","fullname":"Yanina Wainscheinker"},"biverifydate":"2019-12-16T00:00:00.000Z","crunchbaseid":"Ferring Pharmaceuticals","lastupdator":"Maor Perlov","lastupdator_email":"maor.perlov@sncentral.org","creator":"Natalia Golczar","creator_email":"ngolczar@gmail.com","createdate":"2016-08-23T00:00:00.000Z","lastupdatedate":"2022-11-04","hide_reason":null,"hide_reason_data":null,"logokey":"$P8C2psQeuYC2QBOslX9XrE3ycx16htRV90zBuyeUuZUMEwdYTGANdS","name":"Ferring Pharmaceuticals","israeliacquisitions":1,"forbesranking":null,"investmentarm":null,"investmentarmname":null,"hubname":null,"acquired_amount":null,"acquired_by":null,"acquired_country":null,"acquired_month":null,"acquired_year":null,"type":"Multinational","formernames":[],"alternativenames":[""],"country":"Switzerland","inisraelsince":"1/2005","inisraelsincemonth":"1","isisraeli":0,"marketcapital":null,"marketcapitaldate":null,"oneliner":"Pharmaceuticals","website":"http://www.ferring.com/en/home/","employees":"51-200","employees_exact":57,"employees_overall":"5,001-10,000","employees_overall_exact":6254,"sociallinks":{"twitter":"https://twitter.com/ferring?lang=en","youtube":"https://www.youtube.com/channel/UCOgiZvHCYjjxcP5ljzwrs-A","facebook":"https://www.facebook.com/ferringpharmaceuticals","linkedin":"https://www.linkedin.com/company/163789","instagram":"https://www.instagram.com/ferringpharmaceuticals/?hl=en"},"social":["https://twitter.com/ferring?lang=en","https://www.linkedin.com/company/163789","https://www.instagram.com/ferringpharmaceuticals/?hl=en","https://www.youtube.com/channel/UCOgiZvHCYjjxcP5ljzwrs-A","https://www.facebook.com/ferringpharmaceuticals"],"flattenedsociallinks":"https://twitter.com/ferring?lang=en|https://www.linkedin.com/company/163789|https://www.instagram.com/ferringpharmaceuticals/?hl=en|https://www.youtube.com/channel/UCOgiZvHCYjjxcP5ljzwrs-A|https://www.facebook.com/ferringpharmaceuticals","apps":{"appstore":"","googleplay":""},"investmentstage":[],"about":"Ferring Pharmaceuticals is a research-driven biopharmaceutical company devoted to identifying, developing, and marketing products in the fields of reproductive health, urology, gastroenterology, endocrinology, and orthopedics. The company's research activities and products are connected by a common focus of providing tailored treatments that work on the body's own terms, enabling doctors to combat numerous diseases and medical conditions.\n\nWith the acquisition of the Israeli company Bio-Technology General (BTG) in 2005, Ferring gained capabilities in recombinant biotechnology as well as more traditional pharmaceutical manufacturing. There are two Ferring sites in Israel: Ferring Pharmaceuticals Israel, a manufacturing and distribution site, and Bio-Technology General, which is involved in the development of recombinant biologics and biotechnology, as well as manufacturing. Ferring and BTG actively search for in-licensing opportunities and product acquisitions in Ferring's key areas of therapeutic activity, reproductive health, endocrinology, urology, gastroenterology, and orthopedics.","founded":"1/1950","team":[{"name":"Doron  Friedman","email":"doron.friedman@ferring.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAwO7jtdYJDA","bounced":false,"claimed":0,"founder":0,"urlname":"doron-friedman-3","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDAnsz_kQkM","position":"General Manager at Ferring Israel","last_name":"Friedman","claimtoken":"z0p9iwI9auhcn1zLgWk29xuLq5hKIeP7ysoVCw0sSwxUFj4lsvmS1x","first_name":"Doron ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/doron-friedman-515b5a5/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-11-04 13:16:07.000000","initials":"DF","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"portfolio":[{"name":"BTG","hidden":false,"raised":"$26.93M","founded":"1980","fullurl":"/company_page/btg-bio-technology-general","logokey":"$z9OMjnaNOrlNYAgvJuOia25w4MpmHXqjhXNma3J7hQvODZ9xl7qBle.jpeg","urlname":"btg-bio-technology-general","employees":"201-500","company_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN7no4wLDA","description":"Genetically Engineered Drugs","fundingstage":"Acquired","businessmodel":"B2B2C","raisedNumber":26930000,"logourl":"https://storage.googleapis.com/clean-finder-353810/$z9OMjnaNOrlNYAgvJuOia25w4MpmHXqjhXNma3J7hQvODZ9xl7qBle.jpeg","style":"","hiddenCompanyTooltip":""}],"exits":[],"mediagallery":[],"affiliatedOrganizations":[{"id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN7no4wLDA","name":"BTG","type":"Startup","hidden":false,"fullurl":"/company_page/btg-bio-technology-general","logokey":"$z9OMjnaNOrlNYAgvJuOia25w4MpmHXqjhXNma3J7hQvODZ9xl7qBle.jpeg","logourl":"https://storage.googleapis.com/clean-finder-353810/$z9OMjnaNOrlNYAgvJuOia25w4MpmHXqjhXNma3J7hQvODZ9xl7qBle.jpeg","onClick":"","visibilityClassName":"","visibilityTooltip":""}],"address":{"israeli":[{"id":"8fe2ca08-60a8-4853-855d-9ca75edf2885","city":"Kiryat Malakhi","type":["R&D"],"address":"Kiryat Malakhi, Israel","placeid":null,"notactive":0,"openeddate":"2005-01-01","registrarid":"510861370","firstrdcenter":0,"registrarname":"Bio-technology General (Israel) Ltd"},{"id":"AW3QbNF13yu6g2hF7epFUlsAATW5CAoTxvNbOY9dLjT2U8CIuqWevs","city":"Caesarea","type":null,"address":"Ha-Shita St 8, Caesarea, Israel","placeid":null,"notactive":0,"openeddate":"1999-03-01","registrarid":"512763053","firstrdcenter":0,"registrarname":"FERRING PHARMACEUTICALS LTD."}],"officesabroad":[{"id":"sXLZ4onKqPcCHVNTwYtSJ8gHh7UsqzZBUDFiOLe8hVxB4qP7oPLsJ6","city":"Saint-Prex","address":"Chem. de la Vergognausaz 50, 1162 Saint-Prex, Switzerland","country":"Switzerland","placeid":null}]},"headquarter_address":"Chem. de la Vergognausaz 50, 1162 Saint-Prex, Switzerland","news":[{"id":"xt67n745Kui3HYHE3EnArWJZ43p86KZUG2fVn2flxj8Gkv9dJ0EIyz","date":"May 19, 2021","link":"https://www.mobihealthnews.com/news/emea/israeli-startup-cytoreason-joins-forces-ferring-pharmaceuticals-find-new-ibd-treatment","source":"www.mobihealthnews.com","visible":1,"analysis":{"tags":"partnership, drug discovery, AI","company":"CytoReason","layoffs":null,"summary":"Israeli startup CytoReason has partnered with Ferring Pharmaceuticals to develop new treatments for inflammatory bowel disease (IBD). CytoReasons AI platform will be used to build cell-centred disease models, allowing Ferring to accelerate drug discovery and reduce costs. The collaboration aims to provide new therapeutic options for IBD patients by identifying top drug targets. CytoReasons computational model simulates human disease on a cellular level, minimizing the need for animal trials and improving the accuracy of human trials. This partnership is the first between the two companies. CytoReasons technology is already used by six of the worlds top 10 pharma firms.","partners":["Ferring Pharmaceuticals"],"customers":null,"investors":null,"confidence":8,"key_topics":["partnership","drug discovery","AI","inflammatory bowel disease","CytoReason"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"CmDQWd0MTG05iWcV1OEFWlWEhoBb6XJaAyJw4k0xXYIUvjzZkMvI0Q","news_summary":"Israeli startup CytoReason joins forces with Ferring Pharmaceuticals to find new IBD treatment","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"4e5daf0d-ca85-4475-8fb7-fbf15b7ef793","date":"Feb 17, 2021","link":"https://www.biospace.com/article/releases/ferring-rebiotix-and-mybiotics-collaborate-to-develop-live-microbiome-based-therapeutics-in-reproductive-medicine-and-maternal-health/","source":"www.biospace.com","visible":1,"analysis":{"tags":["microbiome","womens health"],"company":"Ferring Pharmaceuticals","layoffs":null,"summary":"Ferring Pharmaceuticals, Rebiotix Inc., and MyBiotics Pharma Ltd. have announced a strategic collaboration to develop live microbiota-based biotherapeutics for bacterial vaginosis. The collaboration aims to reduce the need for antibiotics and provide a long-term treatment solution for the common vaginal infection. The agreement combines MyBiotics culturing and delivery technologies with Rebiotixs expertise in microbiota-based products and Ferrings therapeutic development and commercial expertise. The collaboration is an important step forward in harnessing the power of the human microbiome in womens health. The partnership between Ferring and MyBiotics has already successfully piloted technologies for stabilizing bacterial species critical to the female reproductive tract. The collaboration is expected to add several firsts to Ferrings microbiome product pipeline, including the companys first non-donor derived formulation and a live microbiota-based product specific to reproductive medicine.","partners":["Rebiotix Inc.","MyBiotics Pharma Ltd."],"customers":null,"investors":null,"confidence":9,"key_topics":["microbiota-based biotherapeutics","bacterial vaginosis","womens health","strategic collaboration","live microbiota"],"date_of_event":"2021-02-17","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"bqwH1G5XttE1tcsS4r2bkpmtAmHC9QgQlUAutwH8Q6vbiUI1KW6Ecp","news_summary":"Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health  BioSpace","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"66797a4a-e08e-4398-8a5e-bcc5ce25145f","date":"Oct 6, 2019","link":"https://www.jpost.com/Jpost-Tech/Biotechnology-General-opens-production-line-to-boost-manufacturing-capacity-603348","source":"www.jpost.com","visible":1,"analysis":{"tags":"pharmaceuticals, production line, investment","company":"Biotechnology General (BTG)","layoffs":null,"summary":"Biotechnology General (BTG), an Israeli-based company, has launched a production line that increases the capacity of mammalian drug production. The company invested $17 million in setting up the production line, which was established at its facilities in the Beer Tuvia Industrial Area in 2018. Ferring Pharmaceuticals, BTGs parent company, provided the investment. The inauguration of the production line was attended by Ferring President Per Falk, who highlighted the importance of BTG in Ferrings goal of becoming a world leader in reproductive medicine and maternal health. BTG is the oldest biological pharmaceutical company in Israel and has expanded over the years to become significant in the production of genetically engineered drugs.","partners":"Ferring Pharmaceuticals","customers":null,"investors":"Ferring Pharmaceuticals","confidence":9,"key_topics":["production line","investment","parent company","genetic engineering","expansion"],"date_of_event":"2018","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$17m","structured_issues":["Investment","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"0a4rH9r2FernaWPROPfssMe83vQkOLZF8uLeza9e8MMD7sNXdQmEzV","news_summary":"https://www.jpost.com/Jpost-Tech/Biotechnology-General-opens-production-line-to-boost-manufacturing-capacity-603348","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"c9e6ec7b-9e45-46d5-a272-cf0f8edca125","date":"Mar 5, 2019","link":"https://en.globes.co.il/en/article-ferring-looks-to-israel-for-innovative-biotech-1001276801?utm_source=spotim&utm_medium=spotim_recirculation&spotim_referrer=recirculation","source":"en.globes.co.il","visible":1,"analysis":{"tags":"pharmaceuticals","company":"Ferring","layoffs":null,"summary":"The article discusses the growth of Swiss company Ferring in the pharmaceutical sector. Ferring has achieved annual revenue of $2 billion by improving the user experience for older products, rather than relying on one bestselling drug. The companys focus on upgrading existing products and expanding into new markets has contributed to its success. Ferring also acquired Bio-Technology General (BTG), an Israeli biotechnology pioneer, which has further strengthened its position in the industry. Ferring is now investing in microbiome products and entering the urological-oncological field. The company aims to reinforce strengths in fertility, urology, and gastroenterology, while also improving access to treatment and the user experience for patients. The article suggests that Ferrings growth strategy could have an impact on the entire pharmaceutical industry.","partners":["Bio-Technology General (BTG)"],"customers":null,"investors":null,"confidence":8,"key_topics":["Ferrings growth strategy","Improving user experience for older products","Acquisition of BTG","Focus on microbiome","Entering the cancer field"],"date_of_event":"March 5, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment","Acquisition"],"acquisition_amount":"$80 million plus additional amounts for milestones and royalties","structuredIssuesShow":"#Investment  #Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"AakjxZvRvPd7eti4F0IOg7QZRuJw7a296zlxpdCawcz2IgppryrKiV","news_summary":"Ferring looks to Israel for innovative biotech","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"f9aa9d60-cece-4f29-9def-64b3d2f1499b","date":"May 23, 2018","link":"http://www.globes.co.il/en/article-ferring-invests-15m-in-israeli-unit-bio-technology-general-1001237498","source":"www.globes.co.il","visible":1,"analysis":{"tags":"expansion","company":"Ferring Pharmaceuticals","layoffs":null,"summary":"Ferring Pharmaceuticals is investing $15 million to expand biotech production capabilities at its Israeli subsidiary Bio-Technology General (BTG). The investment will support the development of new treatments in reproductive medicine and womens health, as well as the manufacturing of the active pharmaceutical ingredient for Ferrings latest fertility treatment. The expansion will allow Ferring to maintain its scientific leadership in the fertility field and help more people around the world. BTG, founded in 1980, is the longest-standing bio-pharmaceutical company in Israel and has an R&D and manufacturing facility for female fertility, growth hormone, and osteoarthritis of the knees.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["biotech production","reproductive medicine","womens health","fertility treatment","BTG facility"],"date_of_event":"May 23, 2018","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$15 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"WV5kTPQrMRR2Dl5KElrZ0Sg4ptuzUyNb3GSl7Cbk46zYpspLL2BCx5","news_summary":"Ferring invests $15m in Israeli unit Bio-Technology General","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"extensions":null,"events":null,"hide_reasons":[{"id":"75T5aG1f0dpqYFonup40lXNjO046zUH82TaHW1TAiIMf9aYAsSOl0d","reason":"No relevant activity"},{"id":"7KVi9S7qqUtO0WCsFclwqBEZluejfNYqWC1Uhx0tPHtDxtvxPPaCPH","reason":"No longer active"},{"id":"hoyKAmu4YJEHmhtLwCdeFldSnDwaVbPXOnH0RA9hKHCzAcHO6OOrXd","reason":"Pending approval"},{"id":"TC54H7CXyKO8GmPECkbyKJf8n34r70JlfJTJHfo85exRpLaKI1Efs9","reason":"Pending approval - External entity"}],"timeline":[],"techcommunityinvolvement":null,"tags":["biotechnology","medical-devices","pharmaceuticals","pain-relief","fertility","drug-development"],"investments":[],"funds":[],"databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"5,001-10,000","fundingtype":"Multinational","parsedName":"Ferring Pharmaceuticals","logourl":"https://storage.googleapis.com/clean-finder-353810/$P8C2psQeuYC2QBOslX9XrE3ycx16htRV90zBuyeUuZUMEwdYTGANdS","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$P8C2psQeuYC2QBOslX9XrE3ycx16htRV90zBuyeUuZUMEwdYTGANdS","teamMembersNumber":1,"nationality":"Foreign","communityinvolvement":[],"popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none"},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}